Try our Advanced Search for more refined results
Liquidia Technologies, Inc. v. United Therapeutics Corporation
Case Number:
Case Type:
IPR
Status:
Final Written Decision
Petitioner:
Liquidia Technologies, Inc.
Patent Owner:
United Therapeutics Corporation
Tech Center:
1600
-
Filed: January 07, 2021 00:00
Coverage
-
July 20, 2022
PTAB Axes Hypertension Drug IP Involved In Generic Fight
The Patent Trial and Appeal Board has invalidated a United Therapeutics Corp. patent on Tyvaso, its inhalable treatment for pulmonary hypertension, giving a boost to efforts by challenger Liquidia Technologies Inc. to obtain federal approval for a generic version of the drug.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Search PTAB cases and full-text documents.
- Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
- Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
View the PTAB case documentsAlready a subscriber? Click here to login
-
July 20, 2022